Introduction: Hepatitis B virus is primarily hepatotropic, causing chronic hepatitis B in 5-10% of patients. Chronic hepatitis B (CHB) infection is a dynamic process, which may have five phases: immunotolerant, immunoactive, latency phase, reactive and HBsAg negative phase. Aim: Analyze clinical and biochemical parameters in relation to morphological condition of the liver. Material and Methods: The study enrolled 35 patients diagnosed with CHB, 24 males and 11 females, aged between 12 and 62 years, in the period 2015-2016. The diagnosis was based on serological, biochemical results, and liver biopsy. In patients in an ELISA assay demonstrated the presence of HBsAg in serum. Results: The study shows that middle-aged male patients are more prone to chronic hepatitis B infection. Most patients have one or two symptoms.Fatigue and right subcostal pain are most commonly present in the groups with fibrosis in second- and third-degree,and hepatomegaly in the group with fibrosis in first-degree. Splenomegaly is present only in groups with fibrosis in third and fourth degree. Elevated average aminotransaminase levels reflected the degree of fibrosis. Significant statistical difference in aminitransaminase levels was confirmed between the group of patients with third- and forth-degree and patients without fibrosis. Conclusion: The increase in ALT levels reflect the degree of fibrosis and cirrhosis of the occurrence. ALT levels may be a predictor of the process of the fibrogenesis, as well as to indicate the degree of fibrosis in HHB infection. Due to frequent discrepancies between clinical manifestations and results of laboratory tests, liver biopsy has been considered “gold standard” for establishing the diagnosis, staging chronic hepatitis B, making therapeutic decisions, monitoring the course of the disease, and assessing prognosis.
Delic D. Hronični virusni hepatitisi. Beograd: Zavod za udžbenike i nastavna sredstva. 2012;
2.
Catherine M, Croagh J, Lubel. Natural history of chronic hepatitis B: Phases in a complex relationship. World J Gastroenterol. 2014;(30):10395–404.
3.
Wong S, Hann H. Hepatitis B-related hepatocellular carcinoma, Critical review. Hepatology. 2013;(1):7.
4.
Delić D. Hronični virusni hepatitis B i C. Moje zdravlje. 2015;
5.
World Health Organiyation P. Hepatitis B vaccine. Wklu Epidemiol Rec. 2015;225–63.
6.
Nelson P, Mathers B, Cowie B. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;57.
7.
Obiekwe O, Chimdia B, Chinyelu O, Olughu E, O. Prevalence and Associations of Hepatitis B Seropositivity in a Rural African Ophthalmic Surgical Population. Open Journal of Ophthalmology. 2016;6–11.
8.
Originalni Radovi.
9.
Ioannou G. Chronic hepatitis B infection: A global disease requiring global strategies. J Hepatology. 2013;839–43.
10.
Johannes C, Jun H, Amy C, Rob J, Ruud B. Metabolic characterization of the natural progression of chronic hepatitis B. Schoeman and Genome Medicine. 2016;
11.
Raoel M, Robert J, Bart J. Management of Thrombocytopenia in Chronic Liver Disease: Focus on Pharmacotherapeutic Strategies, Review Article. J PMC International. 2015;(17):1981–92.
12.
Kumar M, Sarin S, Hissar S. Virologic and histologic features of chronic hepatitis B virus infected asymptomatic patients with persistently normal ALT. Gastroenterology. 2008;1376–84.
13.
Xiao G, Yang J, Yan L. Comparison of Diagnostic Accuracy of Aspartate Aminotransferase to Platelet Ratio Index and Fibrosis-4 Index for Detecting Liver Fibrosis in Adult Patients With Chronic Hepatitis B Virus Infection: A Systemic Review and Metaanalysis. Hepatology. 2015;(1).
14.
Shafaei S, Amiri S, Hajiahmadi M. MD Histological grading and staging of liver and its relation to viral loads in chronic anti-HBe positive hepatitis. Caspian J Intern Med. 2013;(3):681–5.
15.
Nikolić J, Ničković V, Aćimović D. Contemporary aspects of the diagnostics of alcoholic liver disease. Vojnosanitetski pregled. 2012;(10):874–9.
16.
Akiko F, Kohsaku S. Fibrosis progression rates between chronic hepatitis B and C patients with elevated alanine aminotransferase levels. Journal of Gastroenterology. 2008;484.
17.
Youwen T, Yun Y, Xinbei Z, Li C, Danfeng W. Age as a Predictor of Significant Fibrosis Features in HBeAg-Negative Chronic Hepatitis B Virus Infection with Persistently Normal Alanine Aminotransferase.
18.
Biazar T, Yahyapour Y, Hasanjani Roushan M, Rajabnia R. Relationship between hepatitis B DNA viral load in the liver and its histology in patients with chronic hepatitis B. Caspian J Intern Med. 2015;(4):209–12.
19.
Wang H, Xue L, Yan R, Zhou Y, Wang M, Cheng M. Comparison of histologic characteristics of Chinese chronic hepatitis B patients with persistently normal or mildly elevated ALT. PloS one. 2013;(11):80585.
20.
Esmaeelzadeh A, Saadatnia H, Memar B, Amirmajdi E, Ganji A. Evaluation of serum HBV viral load, transaminases and histological features in chronic HBeAg-negative hepatitis B patients. Gastroenterol Hepatol Bed Bench. 2017;(1):39–43.
21.
Zan Y, Zhang Y, Tien P. Hepatitis B virus e antigen induces activation of rat hepatic stellate cells. Biochem Biophys Res Commun. 2013;391–6.
22.
Chao D, Lim K.
23.
Ayoub W. Systematic review with meta-analysis: the proportion of chronic hepatitis B patients with normal alanine transaminase ≤40 IU/L and significant hepatic fibrosis. Aliment Pharmacol Ther. 2014;349–58.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
